1. Introduction {#s0005}
===============

Uterine papillary serous carcinoma (UPSC) tumors are generally associated with aggressive clinical behaviors. UPSC is frequently a component of mixed histology tumor with endometrioid components. Previous studies have suggested controversial conclusions concerning the survival of patients with mixed tumors compared to pure UPSC.

Gilks et al. (2013) suggested that in high grade endometrial cancer, agreement between two reviewers regarding the interpretation of pathological slides was reached in only 25--40% of cases, and final diagnostic consensus among three reviewers was reached in 62.5% of cases ([@b0025]). While tumor heterogeneity may be a contributing factor, this suggests that, even among experienced pathologists, histotype and grade assignment in EC, particularly in large high-grade tumors, is inaccurate, leading to inconsistent categorization of tumors ([@b0025]).

The aim of the current study was to evaluate the prognostic value of preoperative histology of endometrioid carcinoma on survival and to assess whether next-generation sequencing could be used to detect the UPSC or EC features of the post-surgical samples.

2. Materials and methods {#s0010}
========================

2.1. Population and data collection {#s0015}
-----------------------------------

The study was conducted at the division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, a tertiary care hospital in Montreal, Canada. The study is in accordance with the declaration of Helsinki and was approved by the Institutional Review Board (protocol \#2019-1547 and \#15-070), with annual reviews. The study population consisted of 61 consecutive patients with UPSC, identified from our prospectively maintained computerized database composed of 544 consecutive patients who were diagnosed and surgically staged for EC between the years 2008--2015. All cases were originally pre- and post-operatively pathologically evaluated, and reviewed again, double blindly, as part of this study by two experienced gynecologic-pathologists. Both study pathologists agreed on the pre- and post-operative diagnoses 100% of the time, based on the microscopic definition of serous carcinoma, where the specimen consists of at least 10% serous component. Preoperative endometrial biopsies for all 61 cases post-operatively diagnosed with UPSC, were examined ([Fig. 1](#f0005){ref-type="fig"}A). Patients who had initially been diagnosed with UPSC (a concordant diagnosis between the biopsy and the final pathology) were compared to those who had initially been diagnosed with EEC (discordant diagnosis).Fig. 1Study population: (A) Selection criteria. (B) Patient characteristics, final pathology and treatment by preoperative histology.

Overall survival (OS) was defined as time from diagnosis (date of endometrial biopsy) to either last follow-up or death. Progression-free survival (PFS) was defined as the time from surgery to either diagnosed date of recurrence or death. Recurrences were diagnosed clinically or radiologically.

2.2. Sequencing {#s0020}
---------------

8--12 mm sections from fresh frozen surgical blocks of 50 patients were stained with hematoxylin and eosin (H&E) and reviewed by a pathologist. Forty-two samples with carcinoma content of over 90% were selected for subsequent analysis. [Fig. 1](#f0005){ref-type="fig"}A illustrates the selected study population. DNA was extracted with the DNeasy Blood and Tissue Kit (Qiagen, Toronto, ON, Canada). DNA concentration and purity was measured with the NanoDrop ND-100 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Next Generation Sequencing was performed using the Illumina MiSeq platform (Illumina Inc., San Diego, CA). 420 hotspots representing 168 cancer-related genes were targeted (genomic regions targeted listed in [supplementary Table 1](#s0065){ref-type="sec"}). Nimblegene TruSeqLT preparation kit (Illumina Inc., San Diego, CA) was used to prepare the library. The Genome Reference Consortium Human Build 38 (hg38; GCF_000001405.26) was used for the reference alignment.

3. Mutation analysis {#s0025}
====================

Missense variants were annotated *in silico* with the Ensembl Variant Effect Predictor ([@b0075]). We prioritized rare variants with a reported population allele frequency below 1.5% in the gnomAD database ([@b0050]). Synonymous or intronic mutations were removed from the analysis, unless the mutation occurred within three base pairs of a coding exon. The potential pathogenicity of each missense variant was assessed using the following prediction tools: PolyPhen-2 ([@b0005]), Sift ([@b0070]), MCAP ([@b0035]), MutationAssessor ([@b0055]) and REVEL ([@b0030]). Variants were kept if they were predicted as pathogenic by at least three out of five tools. All data manipulations were within the R environment ([www.cran.r-project.org](http://www.cran.r-project.org){#ir005}).

4. Statistical analysis {#s0030}
=======================

Statistical analysis was performed using SPSS 24 (IBM Corp, College Station, TX). Statistical significance was calculated using the chi square or the Fisher's exact tests for differences in qualitative variables and the Wilcoxon rank sum test for differences in continuous variables.

Kaplan-Meier survival curves were used to calculate survival estimates (PFS and OS) and the log rank test was used to quantify survival differences according to different variables. A multivariate analysis using the Cox proportion hazards model was performed to assess the hazard ratio of the prognostic factors for PFS and OS.

5. Results {#s0035}
==========

5.1. Patient characteristics and oncologic outcomes {#s0040}
---------------------------------------------------

Sixty-one patients met the study inclusion criteria diagnosed post-operatively with UPSC on surgical pathology. Fifteen subjects (24.6%) that had been preoperatively diagnosed with EEC were compared to 46 patients (75.4%) with a concordant diagnosis of UPSC ([Fig. 1](#f0005){ref-type="fig"}A).

Patient characteristics are summarized in [Fig. 1](#f0005){ref-type="fig"}B. The median age of the women in the cohort was 71 \[range, 43--85\]. Other clinical characteristics such as BMI and ASA scores were not significantly different between the groups, although patients previously diagnosed with EEC had a trend toward higher BMI compared to patients, originally diagnosed with UPSC (median BMI of 31.3 \[18.4--45.4\] versus 26.2 \[17--53\], p = 0.127). Almost half of patients also had an endometrioid component of at least 10% (mixed tumor) on final pathology. Patients who were biopsied with EEC were more likely to be finally diagnosed with mixed tumors compared to patients with UPSC in their preoperative endometrial sampling (73.3% versus 38.1%, P = 0.036). This association was found to be stronger with higher endometrioid component cut-offs of 25% and 50% (p = 0.002 and p = 0.001, respectively). There were no statistically significant differences in the rate and number of dissected nodes, FIGO stage, myometrial invasion, positive peritoneal cytology, and maximal tumor diameter.

Forty-six (75.4%) and fifty-three (86.9%) women received adjuvant radiation treatment and chemotherapy, respectively, without significant statistical differences between the two groups (p = 0.317 and p = 0.182, respectively).

Data for time-to-event analyses were updated up to Sep 27, 2016. The median follow-up time for all patients was 41.6 months (range, 5.4--106.7 months) with significantly longer follow-up in patients preoperatively diagnosed with EEC (56.9 \[9.6--106.7\] versus 37.1 \[5.4--88.2\], P = 0.038). [Table 1A](#t0005){ref-type="table"} summarizes the survival outcomes of the patients in each cohort. During the follow-up period, seventeen women (27.9%) had recurrent disease and 21 (34.4%) died. In a univariate analysis, a preoperative diagnosis of EEC was associated with significantly better 3-year PFS (100% vs. 60.9%, p = 0.003) and OS (100% vs. 69.6%, p = 0.014), longer disease free interval (63.5 vs. 15 months, P = 0.026) and better survival (66.5 versus 20 months, p = 0.011) compared to women initially diagnosed with UPSC.Table 1APrognosis by initial pathology.VariableAll patients\
N=61Initially UPCS\
N=46Initially endometrioid EC\
N=15P-valueOverall mortality21(34.4%)18(39.1%)3(20%)0.222 3-years survival47(77%)32(69.6%)15(100%)0.014 Median survival time\* (months)24.4(5.4--76.6)20(5.4--50)66.5(42.1--76.6)0.011Recurrence17(27.9%)14(30.4%)3(20%)0.524 Local5(8.2%)5(10.9%)00.321 Distant16(26.2%)14(30.4%)2(13.3%)0.312 3-years progression free survival43(70.5%)28(60.9%)15(100%)0.003 Median time to recurrence\* (months)17.0(5.1--74.4)15(5.1--48.5)63.5(52.7--74.4)0.026

[Fig. 2](#f0010){ref-type="fig"} and [Table 1B](#t0010){ref-type="table"} present the Kaplan-Meier OS and PFS in patients initially diagnosed with EEC compared to patients with a concordant diagnosis of UPSC, adjusted by stage and age in a cox-regression model. Age 70 or greater (hazard ratio 2.4 (95% CI 1.0--6.2), P = 0.055), advanced FIGO stage (16.4 (5.6--48), P \< 0.001), and preoperative diagnosis of EEC (0.2 (0.1--0.8), P = 0.02) significantly impacted PFS. Preoperative diagnosis of EEC also significantly impacted OS 0.2 (0.1--0.9), P = 0.037).Fig. 2Kaplan-Meier survival analyses by initial diagnosis: (A) Overall survival. (B) Progression free survival.Table 1BA multivariate analyses of prognostic factors for OS and PFS in patients with UPSC (n=61).Overall survival 95% confidence intervalProgression free survival 95% confidence intervalRisk factorHazard ratioLowerUpperP-valueHazard ratioLowerUpperP-valueAge[\>]{.ul}705.01.715.00.0042.41.06.20.055Initial diagnosis (Endometrioid vs. Serous)0.20.10.90.0370.20.10.80.020Stage (III/IV)13.44.440.6\<0.00116.45.648.0\<0.001

5.2. Mutational profiles {#s0045}
------------------------

In forty patients who were post-operatively diagnosed with UPSC and also had their tumors sequenced ([Fig. 1](#f0005){ref-type="fig"}A), 54 out of 168 sequenced genes harbored mutations predicted to be pathogenic. Thirteen out of 40 sequenced tumors were misdiagnosed preoperatively as EEC. [Fig. 3](#f0015){ref-type="fig"}A shows a landscape overview of the frequency of mutated genes, the number of mutations per sample and the type of mutation (on final pathology) in function of preoperative pathology. Six samples exhibited a hyper-mutated phenotype (N \> 8 mutations) due to their increased mutational frequency compared to all other samples. Three out of those six samples were preoperatively diagnosed with EEC. *TP53* was found to be the most commonly mutated gene in patients post-operatively diagnosed with UPSC, overall ([Fig. 3](#f0015){ref-type="fig"}A, 80%), but that frequency differed significantly between patients preoperatively diagnosed with EEC and UPSC tumors (61.5% vs. 88.9%, respectively, P = 0.04, [Fig. 3](#f0015){ref-type="fig"}B). *PPP2R1A* was found to be mutated in 40% of patients (23.1% and 48.1% of preoperatively EEC and UPSC, respectively, p = 0.135). *PTEN, PIK3CA* and *ARID1A* were found to be mutated in 22.5%, 20% and 10% of the samples (*PTEN*- 38.5% and 14.8%; *PIK3CA*- 30.8% and 14.8%; *ARID1A*-23.1% and 3.7% of preoperatively EEC and UPSC tumors, respectively, p = 0.09, p = 0.242, p = 0.06).Fig. 3Somatic mutations profiles of patients diagnosed finally with UPSC by their preoperative histology: (A) A landscape overview of the frequency of mutated genes, the number of mutations per sample and the type of mutation. (B) Frequency of the most mutated genes (≥10%).

*FOXO3* and *TUBB4B* were only mutated on final pathology of preoperative EEC tumors. (23.1%, p = 0.01). Interestingly, all four patients in the preoperative EEC group without *TP53* mutations harbor a *PTEN* mutation and did not recur. [Fig. 3](#f0015){ref-type="fig"}B illustrates the most frequently mutated genes in our patient cohort.

6. Discussion {#s0050}
=============

Our findings suggest that women preoperatively diagnosed with UPSC had a 5-fold greater risk for progression and death compared with those initially diagnosed with EEC, even after adjusting for confounding variables. Endometrioid-like mutational features were overrepresented in the final pathology of preoperatively EEC group, which may account for the differences in pathogenesis and prognosis.

Roelfsen et al. compared 58 patients with mixed UPSC to 50 patients with pure UPSC and showed that the major prognostic factors for PFS and OS were stage and pure UPSC pathology ([@b0060]). In this multi-center study, women with pure UPSC histology had a 2.9 and 2.6-fold greater risk for recurrence and death respectively, compared with those with mixed tumors ([@b0060]). Other studies failed to show a significant difference in survival between patients with pure UPSC and those with mixed tumors ([@b0020]). Preoperative biopsy might serve as a fingerprint of the endometrioid component of the tumor, as endometrial sampling results of EEC were found to be associated with a final pathology of mixed tumors in almost three-quarters of patients in this group.

Inter- and intraobserver variability of grade and histotype assignment in relatively large tumors might lead to a discrepancy between preoperative biopsies and surgical specimen ([@b0010]). However, it has recently been shown that molecular classification can be achieved preoperatively and accurately predict the molecular features in the final hysterectomy specimens, demonstrating concordance superior to grade and histotype ([@b0065]). Thus, the endometrioid component of the tumor, sampled before the surgery, may be reflected at the molecular profile of the final pathology specimen.

Patients for whom the initial diagnosis was changed after surgery had significantly less frequent *TP53* mutations in their tumors compared to patients with a concordant diagnosis. *TP53* gene mutations are markers of adverse outcomes in endometrial cancer mostly due to their strong association with UPSC ([@b0015], [@b0040], [@b0045]). Interestingly, in the subset of patients without a *TP53* mutations and preoperative diagnosis of EEC, loss-of-function *PTEN* mutations were found. The TCGA study previously observed this mutual exclusivity between the two genes that suggest distinct oncogenic mechanisms between EEC and UPSC. While histology does not seem to differentiate the two in post-operative surgical samples, next-generation sequencing was able to detect the endometrioid characteristics of a significant proportions of UPSCs. In addition to *PTEN* mutations, *PIK3CA* mutations potentially disrupting the PI3K/AKT pathway were also found more often in preoperative EEC samples. Disruptions in this pathway are a hallmark of endometrioid tumors. Preoperative EEC tumors seem to have strong endometrioid-like characteristics even though they were diagnosed as UPSC after surgery. These molecular differences may account for the survival differences observed in our cohort.

The relatively small number of UPSC tumors and genes analyzed clinically and genetically limits the ability to derive deeper conclusions from our clinical and molecular findings, despite our statistically significant results. Furthermore, our results rely on single tumor biopsy samples (snapshots) to portray tumor mutational profile and should therefore be interpreted carefully, taking into account intratumor heterogeneity. Thus, the genomic landscape of our tumor samples might not reflect all the changes responsible for the significantly different clinical behavior observed in serous tumors, namely those diagnosed initially as endometrioid compared to serous type. However, since EC is a molecularly heterogeneous disease and that UPSCs are often composed of mixed cancer cell populations, our results suggest that next-generation sequencing may be a powerful tool to detect and perhaps quantify the endometrioid and serous components of a particular tumor.

The main strength of this study lies in the fact that this data was collected in a single tertiary center where all the patients were fully staged, including lymphadenectomy, treated, and followed up. The two cohorts that were compared were well balanced with regards to clinical factors as age, ASA, and BMI. Finally, the data for the study was based on prospectively collected and computerized data as reported by gynecologic oncologists directly after the operation and in every follow-up visit thereafter. While misclassification of histology cases is possible, all tumor samples underwent pathology review prior to molecular analysis. Preoperative samples with different histological results than on final pathology were reviewed and examined in our hospital. Moreover, our stringent mutation filtering pipeline allowed us to preferentially consider mutations with putative deleterious effects.

In conclusion, this single-institution study evaluating surgically staged EC patients with UPSC suggests that preoperative EEC fingerprint is significantly associated with better outcomes and a unique mutational profile on final pathology, possibly reflecting a prominent endometrioid component at final pathology and potentially implicating different oncogenic pathways than other UPSC.
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